France
Université de Toulouse - CHU de Toulouse
In situ gene Therapy, Chemosensitization, Plasmidic vector, Gemcitabine, Pancreatic ductal adenocarcinoma, Clusterin, Chemoresistance
preventive screening, genetic screening, Health Literacy, pancreatic cancer, high-risk individuals